Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLLN vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLLN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

BLLN Overall Winner 6-Pillar Tally: BLLN 4 – 2 TWST Matrix Metrics: BLLN 7 – 3 TWST

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Twist Bioscience Corporation (TWST) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin).

  • Composite vs. Pillar Nuance: While TWST currently prints a higher short-term Unified Composite Score (51.7/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -28.8% operating margin) and revenue trajectory (+47.2% vs. +27.9% YoY).
  • Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLLN vs TWST
BLLN US Equity Head-to-Head Winner
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93
TWST NASDAQ
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.04
-5.88% 1D
Market Cap $7.4B
TTM Revenue $459M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.8 · SMA20: $137.31 · SMA50: $149.83

6-Pillar Scorecard Institutional Category Breakdown (BLLN 4 – 2 TWST)

Columns: Metric · BLLN · TWST
1. Valuation Multiples BLLN
Forward P/E 61.3x N/M
Trailing P/E 114.3x N/M
PEG Ratio N/M N/M
EV / Revenue 10.5x 16.1x
2. Growth & Scale BLLN
Revenue Growth (YoY) +47.2% +27.9%
Earnings Growth (YoY) +220.0% +0.0%
TTM Revenue (USD) $437M $459M
Market Cap $5.0B $7.4B
3. Profitability & Quality BLLN
Gross Margin 71.4% 52.4%
Operating Margin 10.2% -28.8%
Net Profit Margin 10.5% -28.3%
Return on Equity (ROE) 13.2% -19.1%
4. Balance Sheet & Cash Flow BLLN
Cash Generation (TTM) $34M -$107M EBITDA
Cash Flow Margin 7.8% -23.4% EBITDA Mgn
Net Cash / Leverage $421M Net Cash $13.61 Book/Sh · -19.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 113.8% (26th %ile) 100.1% (19th %ile)
Put/Call OI Skew 1.21x (Put-Skewed) 1.04x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity 61.2% of Rev ($267M) 81.2% of Rev ($373M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLLN (7) vs TWST (3)
Institutional Metric BLLN TWST Criterion Row Edge
Market Capitalization
Scale
$5.0B $7.4B Larger Scale TWST
Trailing P/E Ratio
Valuation
114.3x N/M Lower Multiple BLLN
Forward P/E Ratio
Valuation
61.3x N/M Lower Multiple BLLN
Revenue Growth (YoY)
Growth
+47.2% +27.9% Higher Growth BLLN
Operating Margin (TTM)
Profitability
10.2% -28.8% Higher Margin BLLN
Net Profit Margin
Profitability
10.5% -28.3% Higher Margin BLLN
Return on Equity (ROE)
Capital Efficiency
13.2% -19.1% Higher ROE BLLN
52-Week Range Position
Momentum
39% ($62–$150) 42% ($23–$220) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
1.44β · 42% Vol 3.13β · 126% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$437M $459M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.4% 52.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.5x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$34M ($421M Net Cash) -$107M EBITDA ($13.61 Book/Sh · -19.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLLN +19.03 pp
BLLN: -1.84% · TWST: -20.87%
3M Horizon BLLN +18.99 pp
BLLN: +9.46% · TWST: -9.53%
6M Horizon TWST +99.14 pp
BLLN: +11.83% · TWST: +110.97%
1Y Horizon TWST +243.75 pp
BLLN: +7.55% · TWST: +251.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BLLN Revenue TWST Revenue BLLN Op. Margin TWST Op. Margin Margin Leader
FY2018 N/A $30M N/A -277.5% TWST
FY2019 N/A $50M N/A -200.1% TWST
FY2020 N/A $90M N/A -155.5% TWST
FY2021 N/A $130M N/A -115.4% TWST
FY2022 N/A $200M N/A -115.3% TWST
FY2023 $70M $250M -96.9% -88.6% TWST
FY2024 $150M $310M -30.9% -70.6% BLLN
FY2025 $310M $380M 5.3% -36.2% BLLN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.1%
IV Percentile 19th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.4B market capitalization and -28.8% operating margin.
OpEx & R&D Reinvestment 81.2% of Rev ($373M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ BLLN vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Twist Bioscience Corporation (TWST) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin). Composite vs. Pillar Nuance: While TWST currently prints a higher short-term Unified Composite Score (51.7/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -28.8% operating margin) and revenue trajectory (+47.2% vs. +27.9% YoY). Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with TWST at +27.9% YoY revenue growth and +0.0% YoY earnings growth on $459M TTM revenue (52.4% gross margin, -28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLLN cumulative revenue shifted +342.9% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 81.2% of Rev ($373M) (0 disclosures) for TWST.

BLLN screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.1x EV/Revenue (-23.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus TWST (-19.1% ROE) capital efficiency.

In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, TWST carries 100.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.